Drug Profile
BMS 582949
Alternative Names: BMS-582949; PS 540446Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Pharmacopeia Drug Discovery
- Developer Bristol-Myers Squibb
- Class Antirheumatics; Benzamides; Skin disorder therapies; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 22 Mar 2011 Discontinued - Phase-II for Atherosclerosis in USA (PO)
- 22 Mar 2011 Discontinued - Phase-II for Plaque psoriasis in Australia (PO)
- 22 Mar 2011 Discontinued - Phase-II for Plaque psoriasis in Canada (PO)